Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platelet reactivity in atrial fibrillation and coronary artery disease under dabigatran versus factor Xa inhibitors
NL-OMON52390Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-blind trial of dabigatran, apixaban, edoxaban, rivaroxaban and acenocoumarol in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by St. Antonius Ziekenhuis. Started Jul 2021; status: active, not recruiting.
02
Drugs
dabigatranapixabanedoxabanrivaroxabanacenocoumarol
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON52390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52390.